In a nutshell This phase 2 trial is evaluating how well daratumumab (Darzalex) works in treating patients with multiple myeloma (MM) that has come back after a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This trial is recruiting in Houston,...
Read MoreMultiple Myeloma Posts on Medivizor
Evaluating busulfan plus melphalan conditioning for patients with multiple myeloma before stem cell transplantation
In a nutshell This study evaluated the safety and effectiveness of busulfan (Myleran) plus melphalan (Alkeran) compared to melphalan alone for patients with multiple myeloma (MM) before autologous stem cell transplantation (ASCT). This study concluded that the combination treatment was more effective for these patients. Some background...
Read MoreEvaluating isatuximab plus pomalidomide and dexamethasone for non-responsive multiple myeloma
In a nutshell This study evaluated isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients. Some background There are several treatment options for patients with MM. Most initial...
Read MoreDoes genetics impact how long patients respond to treatment for recurrent multiple myeloma?
In a nutshell This study evaluated whether certain genetic markers affect how long patients respond to treatment for recurrent multiple myeloma (MM). This study found that patients without these genetic markers had better outcomes compared to patients who did have them. Some background Multiple myeloma is a type of cancer of the bone marrow that can...
Read MoreExpert recommendations for the treatment of patients with multiple myeloma.
In a nutshell This article provided recommendations for the treatment of patients with multiple myeloma (MM). Some background Multiple myeloma is a type of cancer of the bone marrow that can lead to abnormal immune cells. High-dose chemotherapy followed by a stem cell transplant (SCT) remains a key part of treatment for patients with MM. There are two...
Read MoreEvaluating outcomes after salvage stem cell transplantation for patients with recurrent multiple myeloma
In a nutshell This study evaluated the outcomes of patients with recurrent multiple myeloma (MM) after a stem cell transplant (SCT). This study concluded that these patients had a lower quality of life up to 2 years after treatment. Some background Multiple myeloma is a type of cancer of the bone marrow that can lead to abnormal immune cells. For...
Read MoreSearching for patients to try a new treatment for multiple myeloma.
In a nutshell This study will investigate the effects of a new treatment, GSK2857916, in patients with multiple myeloma (MM). Overall response will be the main outcome measured. The details There are many treatment options for MM. However, some patients do not respond to treatments or relapse. New therapies are being developed for these patients....
Read MoreEvaluating carfilzomib plus dexamethasone for newly diagnosed multiple myeloma
In a nutshell This study evaluated the safety and effectiveness of the Kd regimen (carfilzomib, dexamethasone) for patients with newly diagnosed multiple myeloma. This study concluded that this regimen was effective for these patients, with mild side effects. Some background Multiple myeloma (MM) is a type of cancer of the bone marrow that...
Read MoreLooking for patients with multiple myeloma to compare 2 conditioning regimens before stem cell transplantation
In a nutshell This study is evaluating the effectiveness of melphalan (Alkeran) alone compared to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) in patients with multiple myeloma before a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have complete disappearance of all signs of...
Read MoreEvaluating ixazomib maintenance therapy for patients with multiple myeloma
In a nutshell This study evaluated the safety and effectiveness of ixazomib (Ninlaro) given after a stem cell transplant for patients with multiple myeloma (MM). This study concluded that ixazomib maintenance therapy is effective for these patients, with manageable side effects. Some background Multiple myeloma is a type of cancer of the bone marrow...
Read MoreSearching for patients to try a combination treatment for multiple myeloma.
In a nutshell The study will investigate the effects of carfilzomib (Kyprolis), pomalidomide (Pomalyst), and dexamethasone (Decadron) in multiple myeloma (MM). The main outcome that will be measured will be the percentage of patients who have no signs or symptoms of MM after treatment (completed response). This study is recruiting in Georgia, Unites...
Read MoreA combination of clarithromycin, pomalidomide and dexamethasone in patients with relapsed/unresponsive multiple myeloma
In a nutshell This study aimed to investigate the safety and effectiveness of a combination of clarithromycin, pomalidomide, and dexamethasone (the ClaPd regime) in patients with relapsed/unresponsive multiple myeloma who had been treated with lenalidomide. This study concluded that this combination is as effective as other currently used...
Read More
